$-0.19 EPS Expected for SteadyMed Ltd. (STDY); Callaway Golf Co Has 0.99 Sentiment

July 18, 2018 - By Rachel Eickhoff

SteadyMed Ltd. (NASDAQ:STDY) Logo

Callaway Golf Co (ELY) investors sentiment decreased to 0.99 in Q1 2018. It’s down -0.37, from 1.36 in 2017Q4. The ratio turned negative, as 98 hedge funds started new or increased positions, while 99 cut down and sold stock positions in Callaway Golf Co. The hedge funds in our database now own: 81.98 million shares, up from 80.37 million shares in 2017Q4. Also, the number of hedge funds holding Callaway Golf Co in top ten positions increased from 2 to 6 for an increase of 4. Sold All: 33 Reduced: 66 Increased: 64 New Position: 34.

Analysts expect SteadyMed Ltd. (NASDAQ:STDY) to report $-0.19 EPS on August, 10.They anticipate $0.14 EPS change or 42.42% from last quarter’s $-0.33 EPS. After having $-0.39 EPS previously, SteadyMed Ltd.’s analysts see -51.28% EPS growth. The stock increased 0.56% or $0.025 during the last trading session, reaching $4.525. About 431,502 shares traded or 92.24% up from the average. SteadyMed Ltd. (NASDAQ:STDY) has declined 34.29% since July 18, 2017 and is downtrending. It has underperformed by 46.86% the S&P500. Some Historical STDY News: 30/04/2018 – UNITED THERAPEUTICS TO BUY STEADYMED FOR $4.46/SHR IN CASH; 30/04/2018 – United Therapeutics to Acquire SteadyMed Ltd; 07/05/2018 – The Law Offices of Vincent Wong Notifies Investors of an Investigation into SteadyMed Ltd. in Connection with the Sale of the Company to United Therapeutics Corporation — STDY; 02/05/2018 – WeissLaw LLP Investigates SteadyMed Ltd; 30/04/2018 – UNITED THERAPEUTICS TO BUY STEADYMED; 30/04/2018 – United Therapeutics to Acquire SteadyMed Ltd. in $216M Deal; 30/04/2018 – SteadyMed (STDY) ALERT: Johnson Fistel Investigates Proposed Sale of SteadyMed Ltd.; Are Shareholders Getting a Fair Deal?; 07/05/2018 – The Law Offices of Vincent Wong Notifies Investors of an Investigation into SteadyMed Ltd. in Connection with the Sale of the; 02/04/2018 – Cardiome Highlights Partner SteadyMed’s Progress Towards Trevyent NDA Resubmission; 07/05/2018 – United Therapeutics Corporation Reports 43.3% Stake In SteadyMed

Another recent and important SteadyMed Ltd. (NASDAQ:STDY) news was published by Seekingalpha.com which published an article titled: “Merger Arbitrage Mondays – July 9, 2018” on July 09, 2018.

Among 2 analysts covering Steadymed (NASDAQ:STDY), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Steadymed had 2 analyst reports since April 9, 2018 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $1500 target in Monday, April 9 report. The stock has “Market Perform” rating by JMP Securities on Tuesday, May 1.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical firm that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. The company has market cap of $120.48 million. The company's product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology. It currently has negative earnings. The Company’s lead drug product candidate is Trevyent, a development stage drug that combines PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue for treating pulmonary arterial hypertension.

Analysts await Callaway Golf Company (NYSE:ELY) to report earnings on August, 2. They expect $0.47 EPS, up 38.24% or $0.13 from last year’s $0.34 per share. ELY’s profit will be $44.37 million for 10.01 P/E if the $0.47 EPS becomes a reality. After $0.65 actual EPS reported by Callaway Golf Company for the previous quarter, Wall Street now forecasts -27.69% negative EPS growth.

Since January 1, 0001, it had 0 insider buys, and 13 selling transactions for $6.04 million activity.

Callaway Golf Company, together with its subsidiaries, designs, makes, and sells golf clubs, golf balls, golf bags, and other golf-related accessories in the United States and internationally. The company has market cap of $1.78 billion. It offers drivers, fairway woods, hybrids, irons, wedges, and putters. It has a 23.44 P/E ratio. The firm also accessories, such as packaged sets, golf gloves, golf footwear, golf apparel, travel gear, headwear, towels, umbrellas, eyewear, and other accessories under the Callaway Golf, Odyssey, and Strata brand names.

D.C. Capital Advisors Ltd holds 5.19% of its portfolio in Callaway Golf Company for 650,000 shares. Daruma Capital Management Llc owns 3.76 million shares or 3.83% of their US portfolio. Moreover, Bernzott Capital Advisors has 3.81% invested in the company for 1.79 million shares. The Massachusetts-based Copper Rock Capital Partners Llc has invested 2.35% in the stock. Profit Investment Management Llc, a Maryland-based fund reported 167,490 shares.

Callaway Golf Company (NYSE:ELY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.